In the Claims

1.-64. (Cancelled)

65. (Currently Amended) A process for treating fibroses comprising administering a therapeutically effective amount of ~~the~~ a pharmaceutical composition ~~which comprises~~ comprising at least one biocompatible polymer selected from the group consisting of RGTA 1112 (CM_2DPheS_2) and RGTA 1113 (CM_3DTyrS_2) ~~of the following general formula (I):~~

~~$A_aX_xY_yZ_z$,~~

~~wherein:~~

~~- A is $(O\text{-}CH_2\text{-}CH_2\text{-}CO)$,~~

~~- X is $COOH$ or COO^-Na^+,~~

~~- Y is $CO\text{-}CH_2\text{-}CHOH\text{-}CH_2\text{-}SO_3H$ or $CO\text{-}CH_2\text{-}CHOH\text{-}CH_2\text{-}SO_3^-Na^+$, and~~

~~- Z represents at least one functional chemical group, which is different from X and Y, selected from the group consisting of a fatty acid, amino acid, fatty alcohol, ceramide or derivative thereof and nucleotide addressing sequences and which confers supplementary biological or physiochemical properties, or wherein~~

~~- A is a glucose monomer,~~

~~- X is $CH_2\text{-}COOH$ or $CH_2\text{-}COO^-Na^+$,~~

~~- Y is SO_3H or $SO_3^-Na^+$, and~~

~~- a represents the number of monomers A such that the mass of said polymers of formula (I) is greater than approximately 5,000 da,~~

~~- x represents a substitution rate of the monomers A by the groups X, which is between approximately 20 and 150%,~~

~~- y represents a substitution rate of the monomers A by the groups Y, which is between approximately 30 and 150%, and~~

~~- z represents a substitution rate of the monomers A by the groups Z, which is between approximately 0 and 50%.~~

66.-68. (Cancelled)